Gastric Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Gastric cancer is the fourth most common malignant disease in men and the fifth in women. Fibroblast growth factors (FGFs) bind to FGFR, which subsequently undergoes phosphorylation at intracellular tyrosine residues, leading to the activation of downstream signalling. FGFR2 protein overexpression was observed in about 30% of gastric carcinomas and was positively correlated with scirrhous cancer, a diffuse type, invasion depth, infiltration type and a poor prognosis. The amplification of FGFR2 has been evident in approximately 5-10% of gastric cancer patients.
- FGFR2 amplification occurs more
frequently in diffuse-type gastric cancer. However, there was no
association found of FGFR2 amplification with histological subtype.
Thelansis’s “Gastric Cancer Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Gastric
Cancer treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Gastric Cancer across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Gastric Cancer Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment